iShares Healthcare Innovation UCITS ETF USD (Acc) GBP is a equity ETF from iShares tracking the Healthcare Innovation index through physical replication. Domiciled in Ireland and launched in 2016, the fund manages about 982 M € and charges a TER of 0.40% — 40 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares Healthcare Innovation UCITS ETF USD (Acc) GBP competes with 175 other products in the same class and region (Equity, Global): it ranks 42nd by fund size and 72nd by ongoing cost, with a TER of 0.40% against a group median of 0.40%. It has been listed since 2016, 10 years of track record.
On a €10,000 investment the TER costs 40 € a year, against 40 € for the median product in the category.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 16.0% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in USD. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
Irish domicile lets the fund apply the Ireland–US tax treaty, with 15% withholding instead of 30% on US dividends received by the fund.
| Moderna Inc | 2.0% |
| Roivant Sciences Ltd | 1.7% |
| Natera Inc | 1.7% |
| Guardant Health Inc | 1.6% |
| AbbVie Inc | 1.5% |
| Genmab A/S | 1.5% |
| Illumina Inc | 1.5% |
| Lonza Group AG | 1.5% |
| Biogen Inc | 1.5% |
| Merck & Company Inc | 1.5% |
| Borsa Italiana | HEAL | EUR |
| XETRA | 2B78 | EUR |
| Francoforte | 2B78 | EUR |
| London Stock Exchange | DRDR | GBX |
| London Stock Exchange | HEAL | USD |
| Euronext Amsterdam | HEAL | EUR |
| SIX Swiss Exchange | HEAL | USD |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.